20d agoThe FlyBULLISH 67Product/PR
Archived explainer. For the current picture see today's VNDA page.
Why Is VANDA PHARMACEUTICAL (VNDA) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 24, 2026 at 8:25 AM ET · reviewed against 3 wire stories
VANDA PHARMACEUTICAL (VNDA) is drawing unusual attention today. Our newswire has captured 3 stories on VNDA across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
VNDA stock is moving 2.1% higher at the open following the announcement of Orphan Designation for imsidolimab in the treatment of Generalized Pustular Psoriasis by the European Commission. The designation, granted to Vanda Pharmaceuticals, is a regulatory milestone that could provide market exclusivity and other incentives for the development of treatments for rare diseases. This news appears to have driven a gap up from the prior close of $5.28 to an opening price of $5.39.
What Happened
Vanda Pharmaceuticals received Orphan Designation for its drug imsidolimab from the European Commission, a status that recognizes therapies for rare and life-threatening conditions. The company announced the designation in a press release, noting that the approval is based on the drug’s potential to treat Generalized Pustular Psoriasis (GPP). This regulatory endorsement is a key step in the drug’s development pathway and may enhance its commercial prospects. The news was also covered in a report from The Fly, highlighting the European regulatory milestone. A separate announcement from the company regarding the NEREUS™ branded No. 47 entry in an IndyCar race was not directly linked to the stock’s movement.
What The Data Shows
The stock opened with a 2.1% gap up and reached an intraday high of $5.60 before consolidating near $5.46. Volume so far is 0.0M shares, which is 0.0x the 3-month daily average. The stock is currently trading within its 52-week range of $4.27 to $9.94. Vanda remains unprofitable, with a trailing twelve-month EPS of -4.63 and a net margin of -127.4%. Revenue has grown by 6.0% TTM, and the company affirmed its FY2026 sales guidance of $240.000M to $290.000M.
What To Watch
Investors should monitor the company’s upcoming earnings report and any further developments in the regulatory and clinical pathways for imsidolimab. Analyst coverage remains positive, with B. Riley Securities and HC Wainwright & Co. maintaining Buy ratings, albeit with lowered price targets.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VNDA by the numbers
Coverage: 3 stories / 3 sourcesAI sentiment: 60/100 (bullish)Mkt cap: $319M52w: $4.27 to $9.94
The headlines behind the move
20d agoPR NewswireBULLISH 63Product/PR
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's...
21d agoStockTitanNEUTRAL 50General
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D....
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on VNDA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier VNDA move explainers: 2026-08-24